GoodRx (NASDAQ:GDRX) Trading 5.4% Higher

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price traded up 5.4% during mid-day trading on Thursday . The stock traded as high as $44.38 and last traded at $44.38. 6,871 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,610,037 shares. The stock had previously closed at $42.11.

Several analysts have recently issued reports on the company. Credit Suisse Group upped their price objective on GoodRx from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday, September 14th. Deutsche Bank Aktiengesellschaft upped their price objective on GoodRx from $37.00 to $47.00 and gave the company a “hold” rating in a research report on Friday, October 1st. Zacks Investment Research upgraded GoodRx from a “sell” rating to a “hold” rating in a research report on Tuesday. Cowen dropped their target price on GoodRx from $44.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, August 24th. Finally, SVB Leerink initiated coverage on GoodRx in a research note on Sunday, August 15th. They issued a “buy” rating and a $56.00 target price for the company. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $49.65.

The company has a market capitalization of $17.29 billion and a price-to-earnings ratio of -48.30. The company has a quick ratio of 16.43, a current ratio of 16.43 and a debt-to-equity ratio of 0.80. The company has a 50 day simple moving average of $39.53 and a 200 day simple moving average of $36.99.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Thursday, August 12th. The company reported $0.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.07. The company had revenue of $176.64 million during the quarter, compared to analyst estimates of $174.15 million. GoodRx had a negative return on equity of 39.62% and a negative net margin of 50.01%. On average, research analysts forecast that GoodRx Holdings, Inc. will post 0.04 EPS for the current fiscal year.

In other news, insider Babak Azad sold 7,500 shares of the stock in a transaction dated Monday, October 11th. The stock was sold at an average price of $40.91, for a total value of $306,825.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Karsten Voermann sold 12,500 shares of the stock in a transaction dated Wednesday, July 28th. The shares were sold at an average price of $32.75, for a total value of $409,375.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares of the company’s stock, valued at approximately $409,375. The disclosure for this sale can be found here. In the last quarter, insiders bought 817,927 shares of company stock valued at $31,217,412 and sold 875,563 shares valued at $36,997,489. 1.43% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of GDRX. Bridgewater Associates LP bought a new position in GoodRx during the 2nd quarter worth approximately $25,628,000. Stifel Financial Corp lifted its holdings in GoodRx by 176.9% during the 1st quarter. Stifel Financial Corp now owns 185,590 shares of the company’s stock worth $7,242,000 after buying an additional 118,554 shares during the last quarter. Avitas Wealth Management LLC lifted its holdings in GoodRx by 4.8% during the 1st quarter. Avitas Wealth Management LLC now owns 48,616 shares of the company’s stock worth $1,897,000 after buying an additional 2,245 shares during the last quarter. Teacher Retirement System of Texas bought a new position in GoodRx during the 2nd quarter worth approximately $38,657,000. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of GoodRx by 3.0% in the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 16,466 shares of the company’s stock worth $643,000 after purchasing an additional 486 shares during the last quarter. 35.86% of the stock is owned by hedge funds and other institutional investors.

About GoodRx (NASDAQ:GDRX)

GoodRx Holdings, Inc, through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Further Reading: What are popular green investing opportunities?

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.